

There is a current global disruption to the supply of tocilizumab injections due to increasing demand in response to the COVID-19 pandemic. During this period of supply disruption, there may be differing presentations of tocilizumab available for use in NSW Health facilities.

The Clinical Excellence Commission's Medication Safety team has reviewed these presentations to identify potential risks which could lead to prescribing, dispensing or administration errors e.g. differing excipients, packaging variations and/or differing storage requirements. As no differences have been identified, the following products have been deemed **appropriate for use** by NSW Health facilities in place of the Australian registered products.

Please note – the drug name 'tocilizumabum' appears on the product imported from Switzerland (this is the Swiss generic name for tocilizumab).

200 mg/10 mL

 <p>ARTG product</p>	 <p>Product from Canada</p>	 <p>Product from Switzerland</p>	<p>Pack of 1</p>  <p>Pack of 4</p>  <p>Products from Germany</p>
--	--	---	--

400 mg/20 mL

 <p>ARTG product</p>	 <p>Product from Switzerland</p>	<p>Pack of 1</p>  <p>Pack of 4</p>  <p>Products from Germany</p>
---	--	--

Contact CEC-MedicationSafety@health.nsw.gov.au for all medication safety enquiries.